Mensia has developed the most advanced technology platform to leverage neurofeedback in the treatment of a wide range of neurological disorders.


The company is conducting the largest randomized controlled neurofeedback trial ever undertaken in ADHD, which compares the neurofeedback treatment to methylphenidate, the current standard of care. Results of the trial are released for the neuromarkers part in June 2018 and for the clinical part in September 2018.


Towards Personalized Brain Rehabilitation

Using electro-encephalography (EEG), neurofeedback capitalizes on the fact that the human brain is a complex electrical system that is made up of several functional oscillatory networks and has the ability to rewire and rebalance itself whenever these networks are destabilized due to trauma or disease. Neurofeedback acts directly on the real-time electrical footprint of these oscillatory brain networks to modulate them and achieve durable normalization and healing. In short, using neurofeedback allows us to leverage the brain’s innate tendency for neuroplasticity to restore its balance.

Over the past five years, Mensia has worked incessantly to automate, scale, and industrialize neurofeedback, building a programming backbone and an intuitive user-interface that permits our technology to be used in routine clinical practice, as well as in research settings in academia and industry. Mensia has a strong intellectual property estate in personalized brain rehabilitation.


Collaborative programs

Newrofeed H2020

Newrofeed H2020 is a non-inferiority ADHD study, comparing Mensia Koala with the reference drug methylphenidate/Ritalin.


Ybrain creates wearable technology to diagnose and treat neuropsychiatric disorders. Ybrain’s proprietary neuroscience-based medical devices are in clinical studies to assess efficacy and safety in collaboration with top international researchers and doctors.


Inria, the French National Institute for computer science and applied mathematics, promotes “scientific excellence for technology transfer and society”. Inria is a major partner of Mensia, having initiated the research programs that served as the basis for Mensia’s products as early as 2006.


An innovative method of physical rehabilitation for patients with upper-limb surgery and/or Amyotrophic lateral sclerosis (ALS), together with Genious Healthcare and the Brain & Spine Institute.

Mind Your Brain

Mind Your Brain is a project that aims at developing novel, non-invasive processes and products for the improvement of attention and focus in the general population as well as in ADHD patients, using the brain’s natural responses to outside stimuli. Mensia works on this project in collaboration with the Lyon Neuroscience Research Center and Black Sheep Studio.


Mensia collaborates with STARTTS, a program focused on PTSD and run by the New South Wales, Australia Service for the Treatment and Rehabilitation of Torture and Trauma Survivors.